Septerna, Inc. Common Stock (SEPN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
Septerna, Inc. Common Stock (SEPN) Competitors
The companies most similar to Septerna, Inc. Common Stock are Sarepta Therapeutics (SRPT), Ultragenyx (RARE) and Vera Therapeutics (VERA). By market cap, Septerna, Inc. Common Stock ranks 4th of the 13 companies on this page; Legend Biotech (LEGN) is the largest at $3.39B.
Peer Comparison
SEPN's revenue growth of -12.2% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Septerna, Inc. Common Stock (SEPN) | $2.03B | N/A | 20.3x | -61.3% | N/A | -12.2% | 0.00% |
| Sarepta Therapeutics Inc (SRPT) | $1.72B | N/A | 0.8x | -5.9% | -3.2% | -4.5% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Vera Therapeutics Inc (VERA) | $2.03B | N/A | 189.3x | 0.0% | -83.0% | 0.0% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| Nektar Therapeutics (NKTR) | $1.27B | N/A | 23.9x | 0.0% | N/A | -20.4% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Recursion Pharmaceuticals Inc (RXRX) | $1.99B | N/A | 23.1x | 0.0% | -51.8% | 258.5% | 0.00% |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $1.90B | N/A | 168.0x | 0.0% | -104.3% | -100.0% | 0.00% |
| Novavax Inc (NVAX) | $1.41B | N/A | 3.2x | -18.6% | -66.6% | -3.0% | 0.00% |
| Palvella Therapeutics, Inc (PVLA) | $2.23B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Peer median | $1.71B | 266.5x | 6.0x | -0.0% | -59.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Septerna, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Sarepta Therapeutics Inc (SRPT) | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy... | SRPT competitors |
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Vera Therapeutics Inc (VERA) | Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases... | VERA competitors |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| Nektar Therapeutics (NKTR) | Nektar Therapeutics is a biopharmaceutical company. | NKTR competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Recursion Pharmaceuticals Inc (RXRX) | Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry... | RXRX competitors |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based... | ZBIO competitors |
| Novavax Inc (NVAX) | Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases... | NVAX competitors |
| Palvella Therapeutics, Inc (PVLA) | Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from... | PVLA competitors |
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
Frequently Asked Questions About SEPN
Who are Septerna, Inc. Common Stock's main competitors?
The companies most similar to Septerna, Inc. Common Stock include Sarepta Therapeutics (SRPT), Ultragenyx (RARE), Vera Therapeutics (VERA), Nuvation Bio (NUVB) and Nektar Therapeutics (NKTR), listed from the closest match.
Who is Septerna, Inc. Common Stock's biggest competitor?
Legend Biotech (LEGN) is the largest of the similar companies at $3.39B; Sarepta Therapeutics (SRPT) is the closest match by business profile, size, sector and industry.
How does SEPN stock compare with its competitors?
SEPN's P/S is 20.3x against a peer median of 6.0x; its net margin is -61.3% against a peer median of -0.0%.
Which of Septerna, Inc. Common Stock's competitors pays a higher dividend?
Septerna, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Septerna, Inc. Common Stock bigger than its competitors?
No. Septerna, Inc. Common Stock is 4th by market cap among the 13 companies on this page; the largest is Legend Biotech (LEGN) at $3.39B.
SEPN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors